Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Gaurav Shah
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
genetic disorders
rare diseases gene therapy |
| gptkbp:foundedYear |
2015
|
| gptkbp:headquartersLocation |
gptkb:Cranbury,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rocket Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
RP-A501
RP-L102 RP-L201 RP-L301 |
| gptkbp:numberOfEmployees |
100-200 (approximate, 2023)
|
| gptkbp:pipelineIndication |
Danon disease
Fanconi Anemia Leukocyte Adhesion Deficiency-I (LAD-I) PKP2-Associated Arrhythmogenic Cardiomyopathy Pyruvate Kinase Deficiency |
| gptkbp:specializesIn |
AAV-based gene therapies
lentiviral-based gene therapies |
| gptkbp:stockSymbol |
RCKT
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.rocketpharma.com/
|
| gptkbp:bfsParent |
gptkb:RTW_Investments
|
| gptkbp:bfsLayer |
8
|